Amodiaquine - sulfadoxine + pyrimethamine

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.2. Antimalarial medicines > Medicines for chemoprevention

EMLc Codes ATC: P01BA06 P01BD51

Indication	Malaria Code ICD11: 1F4Z
INN	Amodiaquine + sulfadoxine + pyrimethamine
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	**Oral > Solid > dispersible tablet:** 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc) ; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc)
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) Modifié en 2025 (TRS 1064)
Sexe	Tous
Âge	Enfants (1 mois - 12 ans)
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Amodiaquine - sulfadoxine + pyrimethamine
DrugBank	Amodiaquine, Sulfadoxine, Pyrimethamine

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strengths of co-packaged amodiaquine with sulfadoxine + pyrimethamine to the EMLc for seasonal malaria chemoprevention in children.